6550--Reagents and Consumables / Hologic Procurement Base Plus 3 (12/1/2024 to 8/31/2028)

Where this opportunity stands

Every notice posted under solicitation 36C26025P0112 in this department, oldest first.

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

• Note the winner and the end of the period of performance for the recompete.
• Follow the agency to see the next notice for this work.

Who won similar work

8 award notices on SAM.gov in the last 24 months. Matched by: Same office (260-NETWORK CONTRACT OFFICE 20 (36C260)), same NAICS 325413.

Single-winner award sizes (8): middle half $282K to $920K, median $475K; range $99K to $3.0M.

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

• Oct 1, 2026CEPHEID INC$3.0MPurchase of Rapid Syndromic Molecular Testing Reagents for Seattle VAMCNo listed company matched (Materiality N/A)
• Jul 13, 2026STRIPES GLOBAL, INC.$179KALCOR iSED ESR Reagents, Consumables, and Service / Warranty for Lab HematologyNo listed company matched (Materiality N/A)
• Apr 1, 2026QUIDELORTHO SALES COMPANY$99K6640 Blood Bank Testing Reagents, Consumables, and SuppliesMateriality: <0.01% of $QDEL revenue (Low)Calculated as Award Amount divided by the company's trailing twelve-month revenue (SEC 10-Q). Here: $99K award ÷ $2.7B revenue, 12 months to Jun 28, 2026 (SEC 10-Q). SEC
• Jan 22, 2026BRANCH MEDICAL LLC$1.5MDistribution of Biorad Bioplex Reagents and Consumables for Laboratory Tests.Materiality: 0.05% of $GMED revenue (Low)Calculated as Award Amount divided by the company's trailing twelve-month revenue (SEC 10-Q). Here: $1.5M award ÷ $3.1B revenue, 12 months to Jun 30, 2026 (SEC 10-Q). SEC
• Dec 31, 2025WERFEN USA LLC$316KCPRR Laboratory Tests for Portland VANo listed company matched (Materiality N/A)
• Dec 23, 2025REMEL INC.$727KAntimicrobial microtiter broth assays purchase for microbiology susceptibility tests.Materiality: <0.01% of $TMO revenue (Low)Calculated as Award Amount divided by the company's trailing twelve-month revenue (SEC 10-Q). Here: $727K award ÷ $46.3B revenue, 12 months to Jun 27, 2026 (SEC 10-Q). SEC
• Oct 28, 2025REMEL INC.$500K6550--BLOOD CULTURE MEDIA AND AUTOMATED MICROBIAL DETECTION SYSTEM THREE YEAR CPRR INDEFINITE DELIVERY INDEFINITE QUANTITY CONTRACT.Materiality: <0.01% of $TMO revenue (Low)Calculated as Award Amount divided by the company's trailing twelve-month revenue (SEC 10-Q). Here: $500K award ÷ $46.3B revenue, 12 months to Jun 27, 2026 (SEC 10-Q). SEC
• Oct 2, 2025ROCHE DIAGNOSTICS CORPORATION$450K6550--Rapid Molecular Testing via Roche Diagnostics CorporationNo listed company matched (Materiality N/A)

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 7 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.